栄研化学 announced ordinary income of ¥1,616 million for the interim period of the fiscal year ending March 2027. This was below the preliminary forecast of ¥1,640 million, while the full-year ordinary income forecast remained unchanged at ¥2,900 million.
栄研化学 announced its interim results for the fiscal year ending March 2027 on 29 October. Ordinary income was ¥1,616 million, approximately 1.5% below the company's previously indicated forecast of ¥1,640 million.
In its full-year outlook announced on the same day, the company left its forecast for ordinary income unchanged at ¥2,900 million and expects an increase in profit year on year.
The article also mentions related stocks including ＪＣＲファーマ, 参天製薬, オンコセラピー and ネクセラファーマ, together with a link to analytical materials from IFIS Japan.